Clinical Trial Update: Italian Real-World Study of Epcoritamab in Relapsed or Refractory DLBCL

View source ↗

Summary

The document provides details of an Italian real-world study evaluating epcoritamab in relapsed or refractory diffuse large B-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• EPKINLY (EPCORITAMAB-BYSP)

Snippet

Sponsor: Andrés José Maria Ferreri | Conditions: Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Refractory Diffuse Large B-Cell Lymphoma | Status: ACTIVE_NOT_RECRUITING